Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carde

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|January 1, 1992
[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies]P Carde, C Chastang, E Goncalves, et al.
Bone Marrow Transplantation|April 21, 2001
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapyJ M Vantelon, J N Munck, J H Bourhis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-CurieE M Noordijk, P Carde, A M Mandard, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patientsR M'kacher, T Girinsky, S Koscielny, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1990
Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell linesP Carde, L Da Costa, L Manil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastasesP Carde, R Timmerman, M P Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trialR Somers, P Carde, M Henry-Amar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative GroupP Carde, A Hagenbeek, M Hayat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomasD Decaudin, J Bosq, G Tertian, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 1990
Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative GroupM Henry-Amar, M Hayat, J H Meerwaldt, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie|January 1, 1992
[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies]P Carde, C Chastang, E Goncalves, et al.
Bone Marrow Transplantation|April 21, 2001
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapyJ M Vantelon, J N Munck, J H Bourhis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-CurieE M Noordijk, P Carde, A M Mandard, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patientsR M'kacher, T Girinsky, S Koscielny, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1990
Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell linesP Carde, L Da Costa, L Manil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastasesP Carde, R Timmerman, M P Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trialR Somers, P Carde, M Henry-Amar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1993
Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative GroupP Carde, A Hagenbeek, M Hayat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomasD Decaudin, J Bosq, G Tertian, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 1990
Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative GroupM Henry-Amar, M Hayat, J H Meerwaldt, et al.
Pageof 13